【结 构 式】 |
【药物名称】 【化学名称】N-(2,2-Dimethylcyclopentylmethyl)-4-[5-(3,3,3-trifluoropropyl)-1,2,4-oxadiazol-3-yl]benzamide isomer A 【CA登记号】212380-87-5 ((-)-enantiomer), 212380-88-6 ((+)-enantiomer) 【 分 子 式 】C20H24F3N3O2 【 分 子 量 】395.42838 |
【开发单位】Bristol-Myers Squibb (Originator) 【药理作用】Antiarrhythmic Drugs, CARDIOVASCULAR DRUGS, Potassium Channel Blockers |
合成路线1
Amine (III) was synthesized from 2,2-dimethylcyclopentanone (I) by treatment with tosylmethyl isocyanide, followed by reduction of the resultant nitrile (II) with LiAlH4. Condensation of 4-cyanobenzoic acid (IV) with amine (III) produced the corresponding amide (V). Subsequent addition of hydroxylamine to the cyano group of (V) gave rise to the hydroxyamidine (VI). The target oxadiazole derivative was then obtained by condensation of (VI) with 4,4,4-trifluorobutyric acid (VII), followed by cyclization under basic conditions. Separation of the enantiomers was carried out by chiral preparative HPLC.
【1】 LLoyd, J.; et al.; Design and synthesis of 4-substituted benzamides as potent, selective, and orally bioavailable IKS blockers. J Med Chem 2001, 44, 23, 3764. |
【2】 Poss, M.A.; Lloyd, J.; Rovnyak, G.C.; Caulfield, T.J.; Atwal, K.S.; Stein, P.D.; Ahmad, S. (Bristol-Myers Squibb Co.); Benzoic acid derivs. and related cpds. as antiarrhythmic agents. WO 9837068 . |
中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
---|---|---|---|---|---|---|
(I) | 43358 | 2,2-dimethylcyclopentanone | C7H12O | 详情 | 详情 | |
(II) | 43359 | 2,2-dimethylcyclopentanecarbonitrile | C8H13N | 详情 | 详情 | |
(III) | 43360 | (2,2-dimethylcyclopentyl)methylamine; (2,2-dimethylcyclopentyl)methanamine | C8H17N | 详情 | 详情 | |
(IV) | 36897 | 4-cyanobenzoic acid;4-Carboxybenzonitrile;p-Carboxybenzonitrile | 619-65-8 | C8H5NO2 | 详情 | 详情 |
(V) | 52509 | 4-cyano-N-[(2,2-dimethylcyclopentyl)methyl]benzamide | C16H20N2O | 详情 | 详情 | |
(VI) | 52510 | 4-[amino(hydroxyimino)methyl]-N-[(2,2-dimethylcyclopentyl)methyl]benzamide | C16H23N3O2 | 详情 | 详情 | |
(VII) | 14781 | 4,4,4-Trifluorobutyric acid | 406-93-9 | C4H5F3O2 | 详情 | 详情 |